| Billed DRG | 871 — Septicemia or Severe Sepsis without MV >96 hours, with MCC |
| Paid DRG | 872 — Septicemia or Severe Sepsis without MV >96 hours, without MCC |
| Plan type | Commercial PPO |
| Payer action | Paid at DRG 872; downgraded MCC to CC on post-payment audit |
| Disputed delta | Illustrative: $12,000–$18,000 depending on facility rate |
The payer's post-payment audit downgraded DRG 871 to 872 on the following basis:
The auditor's rationale conflates clinical resolution with coding classification. These are distinct standards.
The following documented clinical findings support the coding of AKI as a major complication/comorbidity during this encounter:
| Severity Marker | Record Evidence | Relevance to MCC |
|---|---|---|
| Creatinine trajectory | Baseline 1.1 mg/dL (prior labs, 3 months). Admission 1.8. Day 2: 2.6. Day 3: 3.4 (peak). Day 5: 2.1. Discharge: 1.6. | Greater than 2x baseline rise meets KDIGO Stage 2 AKI criteria. The magnitude of rise, not the resolution, determines whether AKI was present during the encounter. |
| Clinical intervention | IV fluid resuscitation adjusted specifically for renal protection. Nephrotoxic medications held (NSAID, ACE inhibitor). Fluid balance monitored. Urine output tracked hourly on Days 2–4. | These are active clinical interventions specifically targeting the AKI — not passive observation. The resource utilization pattern supports the MCC classification. |
| Physician documentation | Attending progress note Day 3: "AKI — likely ATN in setting of sepsis. Holding nephrotoxins. Renal dosing antibiotics. Will trend Cr and urine output. Nephrology consult if no improvement in 24 hours." | The physician identified, assessed, monitored, and actively managed the AKI as a distinct clinical problem. This meets the standard for a condition that was present and required clinical evaluation and management during the encounter. |
| Medication adjustments | Vancomycin renal-dosed (trough-guided). Metformin held. Lisinopril held. Ibuprofen discontinued. Gentamicin considered and rejected due to renal status. | Multiple medication decisions were made specifically because of the AKI. This represents clinical resource utilization and decision complexity attributable to the complication. |
| Discharge status | Creatinine 1.6 at discharge (above baseline of 1.1). Discharge instructions include nephrology follow-up in 2 weeks and repeat renal panel. Medications remain adjusted. | The AKI had not fully resolved at discharge — creatinine remained elevated above baseline. The ongoing management plan further supports the condition's clinical significance during the encounter. |
"The AKI was transient and resolved with conservative management."
The coding standard for assigning a complication/comorbidity does not require that the condition persist through discharge or require a specific intervention threshold such as dialysis. The standard requires that the condition was clinically present during the encounter and required clinical evaluation, monitoring, or management. AKI with creatinine rise to 3.4 (KDIGO Stage 2), active intervention (fluid management, nephrotoxin hold, renal dosing, hourly urine monitoring), and physician-documented assessment and treatment plan satisfies this standard. Resolution with conservative management does not retroactively eliminate the condition from the encounter record.
"No dialysis was required."
Dialysis is not a prerequisite for AKI to qualify as an MCC. The MCC classification reflects the clinical severity and resource impact of the condition during the hospitalization — not whether a specific procedural intervention was performed. Many conditions classified as MCCs (e.g., respiratory failure managed with supplemental oxygen rather than mechanical ventilation, coagulopathy managed with factor replacement rather than surgical intervention) qualify on the basis of clinical significance, monitoring, and management rather than a procedural threshold.
"The complication did not rise to the level of 'major.'"
The distinction between MCC and CC is a coding classification defined by CMS, not a clinical severity judgment made by the auditor. AKI is classified as an MCC in the MS-DRG system when properly documented and coded. The auditor's rationale applies a clinical-impression standard ("not major enough") rather than the coding standard ("was the condition present, documented, and did it affect management"). The record satisfies the coding standard.
This memo provides the clinical reasoning that supports the MCC classification. The following operational notes are for the CDI specialist and coding professional completing the appeal:
This memo complements your CDI workflow — it does not replace it. The clinical severity argument (why the AKI is real, significant, and actively managed) is Clinovian's contribution. The coding-rule argument (why the MCC assignment is correct under current guidelines) is yours. The strongest appeals combine both.
| Risk | Severity | Mitigation |
|---|---|---|
| Auditor re-applies "resolved = not major" logic | Medium | Pre-empt by citing the coding standard (condition present and managed) vs. clinical outcome standard in the first paragraph of the appeal. Make the distinction unavoidable. |
| Physician documentation lacks explicit "AKI" diagnosis label | Low in this case | The Day 3 note explicitly names "AKI — likely ATN." If this were absent, a compliant physician query would be needed. Not required here. |
| Payer argues creatinine rise was pre-existing CKD progression | Medium | Baseline creatinine of 1.1 from 3 months prior establishes a clear pre-illness baseline. The acute rise to 3.4 is distinct from any chronic trajectory. Include the baseline lab in the appeal packet. |
| Second-level review upholds downgrade | Low | If Level 1 fails, this case is well-suited for external review — the clinical evidence is strong and the auditor's logic has a clearly identifiable error. Build the Level 1 appeal with external review in mind. |
Pursue recovery. The clinical evidence strongly supports AKI as an MCC during this encounter. The payer auditor's downgrade applies the wrong standard — clinical resolution rather than coding classification. The creatinine trajectory, active interventions, medication adjustments, and physician documentation collectively establish that the condition was present, managed, and clinically significant. Combined with the CDI/coding team's guideline citations, this case has strong appealability based on the documented clinical record, subject to final coding validation and payer review.
Illustrative disputed value: $12,000–$18,000 depending on facility-specific DRG rate differential. Not a recovery guarantee. This is one case. The pattern — payer auditors applying clinical-resolution logic to downgrade MCCs — is systematic and likely affects other sepsis, respiratory failure, and AKI-complicated cases in the same audit batch.
For future similar cases: DRG downgrades in sepsis cases are frequently driven by documentation that describes the treatment provided without connecting clinical severity markers to the higher-weighted DRG. If the treating physician had documented the specific clinical indicators of organ dysfunction severity — hemodynamic instability, vasopressor requirements, mechanical ventilation parameters — in the discharge summary (not just the progress notes), the coding team would have had the documentation needed to support the higher DRG at initial billing, before payer audit.
Forward-looking operational insight for the client's physician and CDI teams.
Internal trend tags shown for specimen purposes.
Want this level of reasoning on your own cases?